Challenges of creating effective CARs for cancer therapy

Por Sentman, Charles L.
Publicado em 2013

Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity

Por Barber, Amorette, Sentman, Charles L.
Publicado em 2009

NKG2D receptor regulates human effector T-cell cytokine production

Por Barber, Amorette, Sentman, Charles L.
Publicado em 2011

Cancer immunotherapy using a bi-specific NK receptor- fusion protein that engages both T cells and tumor cells

Por Zhang, Tong, Sentman, Charles L.
Publicado em 2011

Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells ()

Por Zhang, Tong, Sentman, Charles L.
Publicado em 2013

T-bet promotes potent antitumor activity of CD4(+) CAR T cells

Por Gacerez, Albert T, Sentman, Charles L
Publicado no Cancer Gene Ther (2018)

NKG2D CARs as Cell Therapy for Cancer

Por Sentman, Charles L., Meehan, Kenneth R.
Publicado em 2014

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma

Por Smits, Nicole C., Sentman, Charles L.
Publicado no J Clin Oncol (2016)

Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment

Por Barber, Amorette, Rynda, Agnieszka, Sentman, Charles L.
Publicado em 2009

Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors

Por Spear, Paul, Barber, Amorette, Sentman, Charles L.
Publicado em 2013

How chimeric antigen receptor design affects adoptive T cell therapy

Por Gacerez, Albert T., Arellano, Benjamine, Sentman, Charles L.
Publicado no J Cell Physiol (2016)

Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy

Por Zhang, Tong, Lemoi, Bethany A., Sentman, Charles L.
Publicado em 2005

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells

Por Barber, Amorette, Meehan, Kenneth R., Sentman, Charles L.
Publicado em 2011

An NKp30-based chimeric antigen receptor promotes T-cell effector functions and anti-tumor efficacy in vivo

Por Zhang, Tong, Wu, Ming-Ru, Sentman, Charles L.
Publicado em 2012

Regulatory T Cell-based Therapies for Autoimmunity

Por Arellano, Benjamine, Graber, David J., Sentman, Charles L.
Publicado no Discov Med (2016)

Bispecific T cell engagers for cancer immunotherapy

Por Huehls, Amelia M., Coupet, Tiffany A., Sentman, Charles L.
Publicado no Immunol Cell Biol (2014)

Chimeric antigen receptor (CAR) T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF

Por Spear, Paul, Barber, Amorette, Rynda-Apple, Agnieszka, Sentman, Charles L.
Publicado em 2012

NKG2D CAR T cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors

Por Spear, Paul, Barber, Amorette, Rynda-Apple, Agnieszka, Sentman, Charles L.
Publicado em 2013

DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma

Por Wu, Ming-Ru, Zhang, Tong, Alcon, Andre, Sentman, Charles L.
Publicado no Cancer Immunol Immunother (2014)

NKG2D ligands as therapeutic targets

Por Spear, Paul, Wu, Ming-Ru, Sentman, Marie-Louise, Sentman, Charles L.
Publicado em 2013